Related Experiment Video
Updated: Nov 5, 2025
09:28
A Method of Nodose Ganglia Injection in Sprague-Dawley Rat
Published on: November 25, 2014
19.3K
ß-arrestin 2 germline knockout does not attenuate opioid respiratory depression
Iris Bachmutsky1,2, Xin Paul Wei1,3, Adelae Durand1
1Department of Physiology, University of California, San Francisco, San Francisco, United States.
Elife
|May 18, 2021
Summary
Researchers investigated the link between beta-arrestin 2 and opioid-induced respiratory depression. Contrary to prior studies, this research found no connection, suggesting new mechanisms for biased agonists in pain relief without respiratory side effects.
Area of Science:
- Pharmacology
- Neuroscience
- Respiratory Medicine
Background:
- Opioids are effective analgesics but cause life-threatening respiratory depression.
- Biased agonists are designed to provide pain relief without respiratory side effects.
- Previous research suggested beta-arrestin 2 mediates opioid respiratory depression.
Purpose of the Study:
- To re-examine the role of beta-arrestin 2 in opioid-induced respiratory depression.
- To validate the signaling pathway hypothesis for biased agonist development.
Main Methods:
- Utilized beta-arrestin 2-deficient mice.
- Assessed respiratory function in response to opioid administration.
Main Results:
- Found no correlation between beta-arrestin 2 deficiency and altered opioid respiratory depression.
- This contradicts the hypothesis that beta-arrestin 2 signaling is responsible for opioid respiratory depression.
Conclusions:
- The previously proposed mechanism linking beta-arrestin 2 to opioid respiratory depression is not supported.
- The mechanism by which biased agonists may attenuate respiratory effects remains to be elucidated.
Keywords:
Opioidsbiased agonistbreathingmouseneuroscienceopioid induced respiratory depressionß-arrestin 2More Related Videos
Related Concept Videos
01:22Opioid Receptors: Overview
2.8K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
2.8K
01:25Analgesia and Pain Management
1.1K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.1K
01:12GPCR Desensitization
7.0K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.0K
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
612
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
612
01:26Adrenergic Receptors: β Subtype
2.9K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
2.9K
01:20Desensitization and Tachyphylaxis
2.6K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.6K